Clinical study of an oral contraceptive in single monthly dose: quinestrol - quingestanol

• Autores: Rubio L., Boris, González A., Ramón
• Formato: artículo
• Fecha de Publicación: 2015
• Institución: Sociedad Peruana de Obstetricia y Ginecología
• Repositorio: Revista SPOG - Revista Peruana de Ginecología y Obstetricia
• Lenguaje: español
• OAI Identifier: oai:ojs.spog:article/823
• Enlace del recurso: http://www.spog.org.pe/web/revista/index.php/RPGO/article/view/823
• Nivel de acceso: acceso abierto

The author has studied the contraceptive effect of 2 mg. of quinestrol administered the 2nd day and 22 day of the cycle plus 2.5 mg. of quingestanol acetate in the 22 day: 256 women with a total of 2610 cycles were studied; none of the women became pregnant during the treatment. The side effects registered nausea, vomiting, cephalea and mastalgia as well as mucorrhea; in most of the patients these symptoms had dissapeared of the 5th cycle of treatment intermenstrual spotting was observed in the first three months with an incidence of 25% and 24.6% then diminished to 4,9 and 3%. The laboratory data did not show modifications in these women.